Communiqués Iris Acquisition Corp

Actions

IRAA

US89601Y1010

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 11/06/2024			Varia. 5j.	Varia. 1 janv.
11,75 ^USD	+2,62 %		+6,62 %	+13,75 %

23/05	Iris Acquisition Corp présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI
17/04	Iris Acquisition Corp présente ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Iris Acquisition : Submission of Matters to a Vote of Security Holders - Form 8-K	02/01	PU
IRIS ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	02/05/23	AQ
IRIS ACQUISITION CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	18/04/23	AQ
IRIS ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	31/03/23	AQ
IRIS ACQUISITION CORP : Change in Directors or Principal Officers (form 8-K)	19/01/23	AQ
IRIS ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	28/12/22	AQ
IRIS ACQUISITION CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23/12/22	AQ
IRIS ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers (form 8-K)	20/12/22	AQ
Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp	06/12/22	AQ
Iris Acquisition : Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma - Form 8-K	01/12/22	PU
IRIS ACQUISITION CORP : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	01/12/22	AQ
Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments	01/12/22	BU
IRIS ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	21/11/22	AQ
IRIS ACQUISITION CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)	14/10/22	AQ
IRIS ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	01/09/22	AQ
IRIS ACQUISITION CORP Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	19/08/22	AQ
Tribe Capital Growth I : Announces Name Change to Iris Acquisition Corp and Other Management Changes - Form 8-K	27/07/22	PU
IRIS ACQUISITION CORP : Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	27/07/22	AQ
TRIBE CAPITAL GROWTH CORP I : Other Events (form 8-K)	07/06/22	AQ
TRIBE CAPITAL GROWTH CORP I Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23/05/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Iris Acquisition Corp

Actions

IRAA

US89601Y1010

Communiqués

Filtres